C07K 14/05
Epstein-barr virus
Official title: Epstein-Barr virus
C07K14/05 (Epstein-barr virus) appears on 58 US grants and 74 published applications in this corpus.
Search patents in C07K- Granted patents
- 58
- Published applications
- 74
- Assignees
- 49
- Inventors
- 131
- Latest grant
- 3 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 2 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 4 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 2 | 4 |
| 2013 | 2 | 1 |
| 2014 | 3 | 4 |
| 2015 | 2 | 3 |
| 2016 | 4 | 5 |
| 2017 | 1 | 0 |
| 2018 | 2 | 0 |
| 2019 | 3 | 8 |
| 2020 | 6 | 6 |
| 2021 | 2 | 15 |
| 2022 | 5 | 6 |
| 2023 | 11 | 4 |
| 2024 | 10 | 8 |
| 2025 | 2 | 3 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Epstein-BARR virus nucleic acid constructs and vaccines made therefrom, and methods of using same3 Mar 2026US 12,564,628 B2The Wistar Institute of Anatomy and Biology
- Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection9 Sep 2025US 12,410,240 B2The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
- Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses15 Apr 2025US 12,276,665 B2Aicuris Anti-Infective Cures GmbH
- Antigenic Epstein Barr virus polypeptides22 Oct 2024US 12,121,562 B2Sanofi
- Self-assembled nanoparticle containing gB protein of EB virus and preparation method and use thereof24 Sep 2024US 12,098,167 B2Sun Yat-Sen University
- Methods of treating multiple sclerosis using autologous t cells28 Aug 2025US 2025/0270272 A1Atara Biotherapeutics, Inc.
- FGF21 Mutants and Uses Thereof1 May 2025US 2025/0136653 A1Amgen Inc.
- Antigenic Epstein Barr Virus Polypeptides24 Apr 2025US 2025/0127847 A1Sanofi
- Hepatitis C Virus Peptide Compositions and Methods of Use Thereof5 Dec 2024US 2024/0398938 A1The Governors of the University of Alberta
- Methods for generating primary immune cells26 Sep 2024US 2024/0316106 A1AstraZeneca AB
Most cited
By later US patents
- FGF21 mutant fusion polypeptides and uses thereof59US 8,642,546 B2Amgen Inc. · 2014
- FGF21 mutants and uses thereof55US 8,410,051 B2Amgen Inc. · 2013
- FGF21 polypeptides comprising two or more mutations54US 8,034,770 B2Amgen Inc. · 2011
- Uses of FGF21 polypeptides comprising two or more mutations54US 8,361,963 B2Amgen Inc. · 2013
- Recombinant dengue virus antigen comprising the capsid protein leader sequence, full-length prM protein, and full-length E protein50US 8,715,694 B2Altravax, Inc. · 2014